Takeda Pharmaceutical Co. (NYSE:TAK) Shares Acquired by Cerity Partners LLC

Cerity Partners LLC increased its position in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) by 81.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 159,285 shares of the company's stock after acquiring an additional 71,634 shares during the period. Cerity Partners LLC's holdings in Takeda Pharmaceutical were worth $2,369,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Blair William & Co. IL lifted its holdings in shares of Takeda Pharmaceutical by 8.1% in the 4th quarter. Blair William & Co. IL now owns 12,199 shares of the company's stock valued at $162,000 after buying an additional 913 shares during the period. Vise Technologies Inc. raised its holdings in shares of Takeda Pharmaceutical by 3.1% in the fourth quarter. Vise Technologies Inc. now owns 34,635 shares of the company's stock worth $459,000 after acquiring an additional 1,026 shares during the last quarter. Farther Finance Advisors LLC increased its stake in Takeda Pharmaceutical by 29.2% in the first quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company's stock valued at $69,000 after purchasing an additional 1,045 shares during the last quarter. Allspring Global Investments Holdings LLC grew its position in Takeda Pharmaceutical by 5.4% during the first quarter. Allspring Global Investments Holdings LLC now owns 21,373 shares of the company's stock valued at $319,000 after acquiring an additional 1,098 shares during the period. Finally, Allworth Financial LP boosted its position in shares of Takeda Pharmaceutical by 12.7% in the first quarter. Allworth Financial LP now owns 10,797 shares of the company's stock worth $163,000 after buying an additional 1,215 shares during the period. Hedge funds and other institutional investors own 9.17% of the company's stock.

Wall Street Analyst Weigh In

Separately, Morgan Stanley raised Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a report on Wednesday, April 2nd.

Takeda Pharmaceutical Stock Performance

Shares of Takeda Pharmaceutical stock opened at $14.42 on Friday. The stock has a market cap of $45.88 billion, a PE ratio of 65.55 and a beta of 0.23. Takeda Pharmaceutical Co. has a 12 month low of $12.80 and a 12 month high of $15.53. The company has a quick ratio of 0.52, a current ratio of 1.01 and a debt-to-equity ratio of 0.57. The business has a fifty day simple moving average of $14.83 and a 200-day simple moving average of $14.44.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by ($0.08). Takeda Pharmaceutical had a net margin of 2.36% and a return on equity of 10.64%. The firm had revenue of $7.34 billion for the quarter, compared to the consensus estimate of $8.02 billion. On average, sell-side analysts anticipate that Takeda Pharmaceutical Co. will post 1.64 EPS for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.